Total Payments
$5,293
2024 Payments
$1,030
Companies
57
Transactions
251
Medicare Patients
3,514
Medicare Billing
$1.7M
Payment Breakdown by Category
Food & Beverage$4,824 (91.1%)
Education$469.16 (8.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,824 | 243 | 91.1% |
| Education | $469.16 | 8 | 8.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Pharmacyclics LLC, An AbbVie Company | $386.57 | 19 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $367.80 | 20 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $366.91 | 15 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $342.51 | 21 | $0 (2023) |
| Merck Sharp & Dohme LLC | $287.59 | 10 | $0 (2024) |
| PFIZER INC. | $271.44 | 11 | $0 (2024) |
| Astellas Pharma US Inc | $249.42 | 7 | $0 (2024) |
| Janssen Biotech, Inc. | $230.47 | 11 | $0 (2023) |
| ABBVIE INC. | $195.62 | 8 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $169.55 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,030 | 32 | ABBVIE INC. ($195.62) |
| 2023 | $1,172 | 55 | Pharmacyclics LLC, An AbbVie Company ($129.16) |
| 2022 | $1,576 | 92 | Novartis Pharmaceuticals Corporation ($204.73) |
| 2021 | $1,141 | 56 | Janssen Biotech, Inc. ($153.47) |
| 2020 | $91.27 | 3 | Pharmacyclics LLC, An AbbVie Company ($50.01) |
| 2019 | $87.45 | 6 | Pharmacyclics LLC, An AbbVie Company ($50.22) |
| 2018 | $172.87 | 6 | Merck Sharp & Dohme Corporation ($106.48) |
| 2017 | $23.59 | 1 | Celgene Corporation ($23.59) |
All Payment Transactions
251 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $4.79 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $27.49 | General |
| Category: ONCOLOGY | ||||||
| 11/17/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $45.33 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/06/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.95 | General |
| 11/06/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $74.99 | General |
| 11/06/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Monoclonal Antibody | ||||||
| 10/30/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Education | In-kind items and services | $25.95 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $25.09 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2024 | Cumberland Pharmaceuticals, Inc. | SANCUSO (Drug) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $24.20 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $1.65 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: Monoclonal Antibody | ||||||
| 09/05/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Education | In-kind items and services | $23.50 | General |
| Category: Monoclonal Antibody | ||||||
| 09/04/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $67.32 | General |
| Category: Oncology | ||||||
| 08/28/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $31.91 | General |
| Category: Oncology | ||||||
| 08/14/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $30.01 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 07/31/2024 | Cumberland Pharmaceuticals, Inc. | SANCUSO (Drug) | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: ONCOLOGY | ||||||
| 07/17/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $115.92 | General |
| Category: ONCOLOGY | ||||||
| 07/03/2024 | Cumberland Pharmaceuticals, Inc. | SANCUSO (Drug) | Food and Beverage | In-kind items and services | $25.22 | General |
| Category: ONCOLOGY | ||||||
| 06/12/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $8.49 | General |
| Category: ONCOLOGY | ||||||
| 06/05/2024 | Cumberland Pharmaceuticals, Inc. | SANCUSO (Drug) | Food and Beverage | In-kind items and services | $23.14 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $27.30 | General |
| Category: ONCOLOGY | ||||||
| 04/17/2024 | PFIZER INC. | — | Education | In-kind items and services | $96.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 512 | 1,044 | $256,297 | $118,821 |
| 2022 | 26 | 1,113 | 56,949 | $1.9M | $738,773 |
| 2021 | 38 | 1,493 | 77,077 | $2.3M | $840,719 |
| 2020 | 15 | 396 | 20,659 | $151,452 | $50,746 |
Total Patients
3,514
Total Services
155,729
Medicare Billing
$1.7M
Procedure Codes
86
All Medicare Procedures & Services
86 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 133 | 451 | $125,936 | $57,455 | 45.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 126 | 282 | $53,997 | $24,909 | 46.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 71 | 86 | $25,800 | $11,483 | 44.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 53 | 53 | $18,013 | $8,744 | 48.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 73 | 73 | $18,031 | $8,235 | 45.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 28 | 66 | $10,098 | $6,047 | 59.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 28 | 33 | $4,422 | $1,948 | 44.1% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2022 | 20 | 12,000 | $1.2M | $503,647 | 42.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 266 | 675 | $138,980 | $62,210 | 44.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 15 | 2,520 | $93,643 | $42,920 | 45.8% |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | Office | 2022 | 16 | 80 | $117,587 | $21,610 | 18.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 175 | 293 | $40,958 | $18,989 | 46.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 56 | 161 | $64,883 | $16,413 | 25.3% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2022 | 13 | 5,720 | $43,186 | $14,581 | 33.8% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2022 | 12 | 11,250 | $23,850 | $10,081 | 42.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 81 | 81 | $24,444 | $9,088 | 37.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 52 | 55 | $21,640 | $8,113 | 37.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 43 | 94 | $14,661 | $7,599 | 51.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 52 | 125 | $22,625 | $6,409 | 28.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 13 | 70 | $10,850 | $4,009 | 36.9% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2022 | 30 | 16,600 | $7,636 | $2,842 | 37.2% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2022 | 15 | 16 | $5,404 | $2,204 | 40.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 18 | 39 | $7,722 | $1,986 | 25.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 55 | 119 | $5,355 | $1,262 | 23.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 26 | 53 | $5,300 | $1,233 | 23.3% |
About Dr. Srinivasu Chamarthy, MD
Dr. Srinivasu Chamarthy, MD is a Hematology & Oncology healthcare provider based in Troy, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/15/2009. The National Provider Identifier (NPI) number assigned to this provider is 1912137647.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Srinivasu Chamarthy, MD has received a total of $5,293 in payments from pharmaceutical and medical device companies, with $1,030 received in 2024. These payments were reported across 251 transactions from 57 companies. The most common payment nature is "Food and Beverage" ($4,824).
As a Medicare-enrolled provider, Chamarthy has provided services to 3,514 Medicare beneficiaries, totaling 155,729 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 86 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Troy, OH
- Active Since 07/15/2009
- Last Updated 07/20/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1912137647
Products in Payments
- IMBRUVICA (Drug) $482.79
- LIBTAYO (Biological) $419.99
- OPDIVO (Biological) $281.70
- KEYTRUDA (Biological) $239.51
- Rezlidhia (Drug) $169.55
- EPKINLY (Drug) $123.79
- COSELA (Drug) $122.73
- KISQALI (Drug) $118.38
- CABOMETYX (Drug) $115.33
- REBLOZYL (Biological) $113.53
- LUMAKRAS (Drug) $103.41
- Lenvima (Drug) $101.49
- Imbruvica (Drug) $100.23
- ENHERTU (Biological) $93.27
- SANCUSO (Drug) $91.01
- TUKYSA (Drug) $89.81
- Monarch Platform (Device) $81.54
- ZEPZELCA (Drug) $74.55
- Pomalyst (Drug) $71.59
- ERLEADA (Drug) $70.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Troy
Dr. Mitchell Folbe, Md, MD
Hematology & Oncology — Payments: $38,995
Hematology & Oncology $38,995
Dr. Thomas Brown, M.d, M.D
Hematology & Oncology — Payments: $19,045
Hematology & Oncology $19,045
Rajeev Kulkarni, Md, MD
Hematology & Oncology — Payments: $9,840
Hematology & Oncology $9,840
Namrata Patel, Md, MD
Hematology & Oncology — Payments: $7,207
Hematology & Oncology $7,207
Joseph Lavelle, D.o, D.O
Hematology & Oncology — Payments: $383.03
Hematology & Oncology $383.03
Dr. Josephine Dela Cruz, Md, MD
Hematology & Oncology — Payments: $320.31
Hematology & Oncology $320.31